欧美GMP法规检查的现场应对：针对制药企业如何做好欧美药管当局法规检查的准备工作的探讨
摘要
本文讨论制药企业如何做好欧美药管当局法规检查的准备工作包括如何降低或消除法规检查中的常见风险。法规当局对制药企业的检查，通常分为药品上市前的批准前检查，和药品上市后的GMP符合性检查。
出处
《现代包装》
2014年第3期58-58,60,61,共3页
Packaging
参考文献8
-
1FDA, Compliance Program Guidance Manual Program 7356.002, Drug Manufacturing Inspections, 2002.
-
2FDA, Compliance Program Guidance Manual Program 7356.002F, Active Pharmaceutical Ingredient (API) Process Inspection, 2006.
-
3刘禹.GMP环境下的记录管理方法[J].医药工程设计,2012,33(3):22-27. 被引量：6
-
4FDA, Compliance Program Guidance Manual Program 7346.832, Pre-Approval Inspection, 2012.
-
5FDA, Guidance for Industry: Refusal of Inspection or Access to ttACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products, 2001.
-
6FDA, Investigation Operation Meamal, 2013.
-
7EMA, EMA/385898/2013 Rev 16, Compilation of Community Procedures on Inspections and Exchange of lnlbnnation, 2013.
-
8EMA/TGA/FDA/EDQM, EMA/ INS/GMP/129953/2012, Programme to Rationaliselnternational GMP Inspections of active pharmaceutical ingredients/active substances manufacturers, 2012.
二级参考文献8
-
1FDA, Compliance Program Guidance Manual 7356.002f, "Pre- Approval Inspections" , 2010.
-
2FDA, Compliance Program Guidance Manual 7356.002f, "Active Pharmaceutical Ingredient (API) Process Inspection" , 2006.
-
3FDA, Compliance Program Guidance Manual 7356.002, "Drug Manufacturing Inspection" , 2002.
-
4FDA, Guidance for Industry: Refusal of Inspection or Access to HACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products, 2001.
-
5美国国会,FederalFood,Drug,andCosmeticAct,Section301(f).
-
6美国国会众议院司法委员会,Federal Rules of Evidence.Rules607,608,609.
-
7PhRMA CMC Statistics and Stability Expert Teams, Identification of Out-of-Trend Stability Results, 2003.
-
8PhRMA CMC Statistics and Stability Expert Teams, Identification of Out-of-Trend Stability Results (Part I1), 2005.
共引文献5
-
1张玉歌,庞青云,郭洪祝,丛骆骆.基于NuGenesis的仪器检测数据的科学管理[J].中国药事,2016,30(1):17-23. 被引量：5
-
2冯功,梁毅.对完善药品生产企业数据完整性的思考[J].中国药房,2017,28(13):1732-1735. 被引量：15
-
3黄美山,崔小娟.浅谈实验室数据完整性管理[J].中国检验检测,2017,25(6):61-63. 被引量：5
-
4王勇,王丽,张文婕,徐书颖,高嘉政,杨昌雄,李凤婷,李华.辨析GLP体系中的变更与偏离[J].中国药事,2020,34(11):1304-1307. 被引量：3
-
5王勇,缪峰,吴娴,高嘉政,杨昌雄,王丽,张文婕,徐书颖.药物安全性评价GLP规范与SOP的关系及完善质量体系初探[J].药物评价研究,2022,45(8):1684-1688. 被引量：4
-
1Masih Sabet, M.Sc.不同GMP法规间的区别[J].流程工业,2013(1):16-16.
-
2巴西最终淘汰甲胺磷[J].浙江化工,2012,43(8):39-39.
-
3北京机动车排放实验室明年将在亦庄建成[J].润滑油,2007,22(5):9-9.
-
4意大利延长新烟碱种子处理剂使用禁令[J].浙江化工,2011,42(11):34-34.
-
5盘点：2010环球医药大事[J].中国医药技术经济与管理,2011(1):16-17.
-
6如何做好农药原药的全分析试验[J].农化市场十日讯,2012(13):34-35.
-
7欧盟修订GMP法规[J].日用化学品科学,2013,36(6):51-52.
-
8孙彤.浅析如何做好药品分类管理工作[J].科技致富向导,2011(12):263-263.
-
9巴西Milenia公司非法改变农药剂型遭指控[J].今日农药,2009(9):40-40.
-
10药品说明书须注明活性成分或中药药味[J].今日上海,2006(7):61-61.
